Aquestive Therapeutics Faces FDA Setback for Anaphylm Drug Approval
Aquestive Therapeutics stock plunges after FDA identifies deficiencies in Anaphylm application, a sublingual film treatment for severe allergic reactions.
/ 2 items
Aquestive Therapeutics stock plunges after FDA identifies deficiencies in Anaphylm application, a sublingual film treatment for severe allergic reactions.
Japan approved neffy (epinephrine nasal spray). This needle-free option treats severe allergies (anaphylaxis) in adults and kids (>15 kg). It's the first in Japan, offering a compact, injection-free alternative. Availability starts late 2025.